Dose intensification and breast cancer: Current results and future perspectives

Annals of Oncology

Volumn 7, Issue SUPPL. 2, 1996, Pages 31-40

  Antoine, E C ^a   Khayat, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Autologous bone marrow transplantation; Breast neoplasms; Chemotherapy; Dose intensity; Dose response; Inflammatory disease; Metastatic disease; Peripheral blood stem cells; Review

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; FORECASTING; HUMAN; METASTASIS; MORTALITY; PATHOLOGY; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 2342593423     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_2.31     Document Type: Review

References (52)

1. Frei E III, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-93.
2. Bonnadona G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-5.
3. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-70.
4. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 1994; 330: 1253-9.
5. Carmo-Pereira J, Costa FO, Henriques E et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471-3.
6. Tannock I, Boyd N, De Boer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
7. Honkoop AH, Pinedo H. High dose chemotherapy in the treatment of breast cancer (Review). Int J Oncol 1995; 6: 911-8.
8. Antman K, Souhami RL. High-dose chemotherapy in solid tumors. Ann Oncol 1983; 4: S29-S44.
9. Pinedo HM. Dose effect relationship in breast cancer. Ann Oncol 1993; 4: 351-7.
10. Vaughan WP. Autologous bone marrow transplantation in the treatment of breast cancer: Clinical and technologic strategies. Semin Oncol 1993; 20 (Suppl 5): 55-8.
11. Jones RB, Shpall EJ, Schogan J et al. The Duke AFM Programme: Intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431-6.
12. Kennedy MJ, Beveridge RA, Rowley SD et al. High dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-6.
13. Antman K, Ayash L, Elias A et al. A phase II study of high dose cyclophosphamide, thiotepa and carboplatin with autoloous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102-10.
14. Dunphy FR, Spitzer G. Use of very high dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst 1992; 84: 128-9.
15. Williams SF, Gilewski T, Mick R et al. High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 1992; 10: 1743-7.
16. Dillman RO, Barth NM, O'Connor A et al. Autologous bone marrow transplantation in breast cancer. Breast Cancer Res & Treat 1993; 18: 182 (Abstr).
17. Vaughan WP, Reed EC, Edwards B et al. High-dose cyclophosphamide, thiotepa, and hydroxyurea with autologous hematopoietic stem cell rescue: An effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619-24.
18. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-9.
19. Shpall E. Is high-dose chemotherapy an established treatment for breast cancer? Proc Am Soc Clin Oncol 1995; 14: A967 (Abstr).
20. Eddy D. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992; 10: 657-70.
21. Hortobagyi GN, Frye D, Buzdar AU et al. Complete remissions in metastatic breast cancer. Proc Am Soc Clin Oncol 1988; 7: 37 (Abstr).
22. Fisher B, Bauer M, Wickerman L et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983; 52: 1551-7.
23. Nemoto T, Vana FJ, Bedwani RN et al. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917-24.
24. Dimitrov N, Anderson S, Fisher B et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22. Proc Am Soc Clin Oncol 1994; 13: 64 (Abstr).
25. Tajima T, Tokuda Y, Kubota M et al. Adjuvant chemotherapy supported by autologous bone marrow transplantation in breast cancer. Proc Am Soc Clin Oncol 1990; 9: 31 (Abstr).
26. Van der Graaf WTA, Willemse PHB, Sleijfer DT et al. Intensive chemotherapy with autologous bone marrow reinfusion in premenopausal breast cancer patients with over 5 positive lymph nodes. Breast Cancer Res and Treat 1993; 18: 184 (Abstr).
27. Overmoyer B, Dannley R, Goormastic M et al. Consolidation for high risk breast cancer with high dose chemotherapy and autologous bone marrow rescue. Proc Am Soc Clin Oncol 1994; 13: 93 (Abstr).
28. Schwartzberg L, Birch R, Hazelton B et al. High dose chemotherapy with peripheral blood stem cell support for high risk stage II and Stage III breast cancer. Proc Am Soc Clin Oncol 1994; 13: 97 (Abstr).
29. Gianni AM, Sienna S, Bregni M et al. 5-Year results of high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with > 10 positive nodes. Proc Am Soc Clin Oncol 1995; 14: 90 (Abstr).
30. Peters WP, Bery D, Vrendenburgh JJ et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving > 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 1995; 14: 317 (Abstr).
31. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
32. Allred DC, Clark GM, Tandon AK et al. HER-2/Neu in node negative breast cancer. Prognostic significance of over-expression influenced by presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
33. Muss HB, Thor AD, Berry DA et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 1994; 330: 1260-6.
34. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: A review. J Clin Oncol 1992; 10: 1014-24.
35. Palangie T, Mosseri V, Mihura J et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994; 7: 921-7.
36. Feldman LD, Hortobagyi GN, Buzdar AU et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-81.
37. Maloisel F, Dufour P, Bergerat JP et al. Results of initial doxorubicin, 5-fluorouracil and cyclophosphamide combination chemotherapy for inflammatory carcinima of the breast. Cancer 1990; 65: 851-5.
38. Gisselbrecht C, Devaux Y, Extra JM et al. Autologous bone marrow transplantation (ABMT) after high-dose cyclophosphamide, mitoxantrone, alkeran in breast cancer. Proc Int Congr Anti-Cancer Chemother 1994; 4: 223 (Abstr).
39. Willemse PHB, Mulder NH, Sleijfer DT et al. Intensive ablative chemotherapy with autologous bone marrow rescue in patients with locally advanced breast cancer in complete remission. Eur J Cancer 1991; 27: S39 (Abstr).
40. Sledge GW, Loesch D, Lottisch C et al. Two cycles of high dose chemotherapy with autologous bone marrow rescue as initial therapy for stage IIIB breast cancer. Breast Cancer Res & Treat 1993; 18: 182 (Abstr).
41. Roché H, Chevreau C, Mihura J et al. Intensive induction chemotherapy (FEC-HD), then high dose chemotherapy with autologous bone marrow transplantation as treatment for non metastatic inflammatory breast cancer. Proc Am Soc Clin Oncol 1994; 13: 89 (Abstr).
42. Booser DJ, Hortobagyi GN. Treatment of locally advanced cancer. Semin Oncol 1992; 19 (Suppl 3): 278-85.
43. Miller AM. Hematopoietic growth factors in autologous bone marrow transplantation. Semin Oncol 1993; 20 (Suppl): 88-95.
44. Nemunaitis J. Use of hematopoietic growth factors in marrow transplantation. Curr Opin Oncol 1994; 6: 139-45.
45. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral blood stem cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-70.
46. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
47. + selected versus standard peripheral stem cell (PSC) rescue following high-dose chemotherapy (HDCT) in patients (PT) with breast cancer (BC). Proc Am Soc Clin Oncol 1994; 13: 104 (Abstr).
48. Goldie JH. Arguments supporting the concept of non-cross resistant combinations of chemotherapy. Cancer Invest 1994; 12: 324-8.
49. Ho AD, Glück S, Germond C et al. Long-term outcome after high-dose chemotherapy with stem cell support for metastatic breast cancer. Proc Am Soc Clin Oncol 1994; 13: 96 (Abstr).
50. Stemmer S, Jones RB, Shpall EJ et al. High-dose Taxol in combination with cyclophosphamide and cisplatin with autologous hematopoietic progenitor cell support for refractory breast and ovarian cancer patients. Proc Am Soc Clin Oncol 1994; 13: 105 (Abstr).
51. Ghalie R, Richman CM, Adler SS et al. Treatment of metastatic breast cancer with a split course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol 1994; 12: 342-6.
52. Hudis C, Lebwohl D, Crown J et al. Feasibility of adjuvant dose-intensive cyclophosphamide (C) with G-CSF after doxorubicin (A) in women (pts) with high-risk stage II/III resectable breast cancer (BC). Proc Am Soc Clin Oncol 1992; 11: 54 (Abstr).